Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Gotta love this early volume.
MWM, buying any MAAC?
Joined you on ABUS.
That was a 4,565,256 HGEN buy at $6.83.
PR from DNA Sciences. Supports TTTSF's StrainSecure 2.0.
Applied DNA Sciences : CertainT® Platform Support for TruTrace StrainSecure™ 2.0
09/14/2021 | 09:12am EDT
Applied DNA Announces CertainT® Platform Support for TruTrace StrainSecure™ 2.0 for Next Generation Cannabis Tagging, Testing and Tracking Advances Partnership Aimed at Streamlining Cannabis and CBD Cultivator Production, Safety Standards, and Traceability While Increasing Brand Recognition
STONY BROOK, N.Y. September 14, 2021.Applied DNA Sciences, Inc. (NASDAQ: APDN) (Applied DNA or the 'Company'), a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing and nucleic acid-based technologies, today announced that its CertainT® platform has added support for StrainSecure 2.0 by TruTrace Technologies, Inc. (CSE: TTT; OTCQB: TTTSF) ('TruTrace') that builds on the companies' strategic sales, marketing, and technology integration partnership to advance their vision of an integrated, cannabis product validation and authentication supply chain security solution for cannabis companies. The two companies recently announced that Flora Growth ('Flora') will utilize their integrated solution be as part of Flora's global cannabis product validation platform. TruTrace is the developer of a fully integrated blockchain platform for the legal cannabis, food, and pharmaceutical industries.
StrainSecure 2.0 is designed specifically for the cannabis industry and aims to demystify the seed-to-sale process for all relevant stakeholders, including producers, distributors, shippers, government agencies, and consumers, by powering commercial standards via an immutable, shared ledger. Applied DNA's CertainT platform has been integrated into TruTrace's StrainSecure software platform since the launch of the companies' strategic alliance in January 2021.
'Integrating our two platforms brings a unique end-to-end solution to the maturing international cannabis industry. With regulations and compliance standards being implemented worldwide, an integrated offering of StrainSecure 2.0 and CertainT can help cannabis companies meet these standards and provide product authenticity and transparency to end-user customers,' said John Shearman, vice president of marketing and cannabis lead at Applied DNA.
Applied DNA's CertainT platform provides the physical tagging of cannabis products using a unique molecular tag to represent the brand and product. That tag is then tested at key nodes within a domestic or international supply chain. All authentication and chain-of-custody data are captured in the CertainT portal, which integrates with the TruTrace platform and will support StrainSecure 2.0. The molecular tag can be applied to cannabis plants, oils, lotions, tablets, edibles, and packaging to serve as an immutable indicator of authenticity, origin, and provenance.
TruTrace's blockchain-based SaaS software is designed to guarantee product quality and strain genetics throughout global supply chains. Protecting consumers and brands from contaminants and counterfeiting is a key benefit of the platform.
Robert Galarza, CEO of TruTrace, stated, 'Over the past two years and after extensive work with key partners, such as Applied DNA, we've gained a deep understanding of the new challenges facing this industry. Version 2.0 of StrainSecure, as well as its interoperability with CertainT, will allow us to provide clients with turnkey tools specifically designed to support product quality, traceability, customer engagement, and safety.'
Most software systems utilized in the industry are fragmented and are built to manage internal operations, with very little interoperability into secondary systems. This fragmentation leads to increased administrative costs, reduced revenue, and increased risks for stakeholders. To address some of these issues, StrainSecure 2.0 will include several robust features tailored to decrease administrative costs, increase revenue, scale business operations, and highlight product quality. StrainSecure 2.0 also includes a significant number of new features, including full integration into the CertainT® platform, that facilitate higher standards and fuels business growth. One such new feature is the Enhanced Scan Page, which serves as a marketing tool for brands by providing real-time data on products at the package level.
Galarza added, 'The expectations of customers, as it relates to the quality of the products they choose to consume, has never been higher. StrainSecure 2.0 focuses on promoting good actors in the industry and giving them a solution, which unifies their network, mitigates risk, ensures compliance with commercial standards, and creates a safer and more consistent marketplace for their customers. Globally focused hemp and cannabis businesses equip themselves with StrainSecure™ to scale their business.'
About Applied DNA Sciences
Applied DNA is commercializing LinearDNA™, its proprietary, large-scale polymerase chain reaction ('PCR')-based manufacturing platform that allows for the large-scale production of specific DNA sequences.
The LinearDNA platform has utility in the nucleic acid-based in vitro diagnostics and preclinical nucleic acid-based drug development and manufacturing market. The platform is used to manufacture DNA for customers as components of in vitro diagnostic tests and for preclinical nucleic acid-based drug development in the fields of adoptive cell therapies (CAR T and TCR therapies), DNA vaccines (anti-viral and cancer), RNA therapies, clustered regularly interspaced short palindromic repeats (CRISPR) based therapies, and gene therapies. Applied DNA has also established a COVID-19 diagnostic and testing offering that is in the early stages of commercialization and is grounded in the Company's deep expertise in DNA.
The LinearDNA platform also has non-biologic applications, such as supply chain security, anti-counterfeiting and anti-theft technology. Key end-markets include Gov/Mil, textiles, pharmaceuticals and nutraceuticals, and cannabis, among others.
Visit adnas.com for more information. Follow us on Twitter and LinkedIn. Join our mailing list.
The Company's common stock is listed on NASDAQ under the ticker symbol 'APDN,' and its publicly traded warrants are listed on OTC under the ticker symbol 'APPDW.'
Applied DNA is a member of the Russell Microcap® Index.
About TruTrace Technologies
TruTrace Technologies is the developer of fully-integrated software, secured on a blockchain infrastructure, that gives clients' the ability to store, manage, share and immediately access quality assurance and testing details, COAs, as well as motion and movement intelligence on inventory. The platform was specifically designed to power the traceability of testing standards within the legal cannabis, nutraceutical, food and pharmaceutical space with a focus on the authentication of source materials or ingredients used in formulation. For more information, please visit https://www.trutrace.co/.
Forward-Looking Statements
The statements made by Applied DNA in this press release may be 'forward-looking' in nature within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. Forward-looking statements describe Applied DNA's future plans, projections, strategies, and expectations, and are based on assumptions and involve a number of risks and uncertainties, many of which are beyond the control of Applied DNA. Actual results could differ materially from those projected due to its history of net losses, limited financial resources, limited market acceptance, including Applied DNA's ability to successfully enter into commercial contracts for the implementation of its CertainT® platform, shifting enforcement priorities of U.S. federal laws and other international laws relating to cannabis and cannabis derivative products, and various other factors detailed from time to time in Applied DNA's SEC reports and filings, including our Annual Report on Form 10-K filed on December 17, 2020, and Quarterly Reports on Form 10-Q filed on February 11, 2021, May 13, 2021, and August 12, 2021, and other reports we file with the SEC, which are available at www.sec.gov. Applied DNA undertakes no obligation to update publicly any forward-looking statements to reflect new information, events or circumstances after the date hereof or to reflect the occurrence of unanticipated events, unless otherwise required by law.
Investor contact
Sanjay M. Hurry
917-733-5573
[email protected]
Program contact
John Sherman
631-240-8838
[email protected]
Attachments
Original document
Permalink
Disclaimer
Applied DNA Sciences Inc. published this content on 14 September 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 14 September 2021 13:11:02 UTC.
TTTSF (.0475) TruTrace Technologies launches 2.0 version of its StrainSecure cannabis-tracking technology
The new version adds a number of new features to the blockchain-enabled technology, such as expanded API capabilities and digital documentation system.
Other improvements include a real-time collaboration module, a detailed inventory management system, and risk mitigation and recall prevention tools
TruTrace Technologies Inc has launched a new version of its proprietary cannabis-tracking platform StrainSecure.
The 2.0 version of the platform adds a number of new features to the blockchain-enabled technology, such as expanded API capabilities and digital documentation systems.
Most notably, the enhanced scan page gives brands a fully-customizable solution to showcase their product’s quality to consumers and market directly from a scan of their packaging.
READ: TruTrace Technologies to roll out cannabis validator with top cannabis cultivator Flora Growth
Other improvements include a real-time collaboration module, a detailed inventory management system, and risk mitigation and recall prevention tools.
"Over the first two years of our business, and after extensive work with leading organizations such as Shoppers Drug Mart (Loblaws), University Health Network, and Deloitte, we’ve gained a deep understanding of the new challenges facing this industry. The second version of StrainSecure will allow us to provide our clients with turnkey tools specifically designed to support the quality of their products and increasing engagement with their customers,” TruTrace CEO Robert Galarza told shareholders in a statement.
According to Vancouver-based TruTrace, most software systems utilized in the industry are fragmented or built only to manage internal operations, which leads to increased administrative costs, reduced revenue and more risks. StrainSecure 2.0 is designed to decrease administrative costs, increase revenue, scale business operations and highlight product quality, the company noted.
Riviera Beverages COO Tony Antillon said that implementing StrainSecure could reduce or prevent recalls, keeping a company from “crippling losses".
"The technology developed by TruTrace is revolutionary not only in its ability to showcase good management practices in action, but also the ability to mitigate significant recall risks in the consumer packaged goods space," Antillon told investors.
"The costs associated with a recall are extremely high as manufacturers must cover costs on a per-store and per-item basis with lack of transparency and traceability being a major contributing factor.”
TruTrace develops fully integrated software, secured on a blockchain infrastructure, that allows brands to store, manage, share, and immediately access quality assurance and testing details, COAs, as well as motion and movement intelligence on inventory.
Contact Angela at angela@proactiveinvestors.com
Follow her on Twitter @AHarmantas
No mention of Shoppers in the financials, and TruTrace hasn't updated investors on much of anything, so I was concerned the collaboration had quietly ended. Also, no press release from TTTSF today. Wondering if they're still working with Clever Leaves (CLVR) on a similar project.
AMC and GME teaser. Gotta love it.
AMC Entertainment CEO teases possible partnership with GameStop
Sep. 08, 2021 3:57 PM ETGameStop Corp. (GME), AMCBy: Clark Schultz, SA News Editor23 Comments
AMC Entertainment Holdings (AMC -0.8%) CEO Adam Aron says the company has made contact with GameStop (GME +0.6%) on a partnership of some sort, but says it is not ready to divulge the nature of the offer.
In general, the theater operator says it is on the offensive to get moviegoers back into the theater with an "epic" $25M advertising blitz.
Nice news for TTTSF (.0438)
Flora Growth Launches Cutting-Edge Global Cannabis Distribution Strategy, Implements Pharmaceutical Standards For Its Supply Chain.
Flora will use TruTrace’s blockchain-enabled platform for seed-to-sale tracking of its cannabis products – including integration of Applied DNA’s molecular tagging technology – to offer Flora’s customers a complete product validation and authentication solution
Flora’s new platform for consumers, distributors, and government regulators will demonstrate its commitment to operational excellence and transparency enabling end-to-end supply chain validation, setting a new global standard for cannabis distribution
Flora will now have the ability to quickly and efficiently reference and manage information at its cultivation and extraction facility, collect and analyze data, derive insights to find cost efficiencies, and ensure accuracy
MIAMI & TORONTO, September 08, 2021--(BUSINESS WIRE)--Flora Growth Corp. (NASDAQ: FLGC) ("Flora" or the "Company"), a leading all-outdoor cultivator and manufacturer of global cannabis products and brands, is pleased to announce it has signed agreements with TruTrace Technologies, Inc. (CSE: TTT; OTCQB: TTTSF) ("TruTrace") and Applied DNA Sciences, Inc. (NASDAQ: APDN) ("Applied DNA") to launch a complete and differentiated global cannabis product validation and authentication platform for consumers, distributors, and government regulators. This initiative further demonstrates Flora’s commitment to operational excellence and transparency enabling immutable genome-to-sale supply chain validation for domestic and international trading partners and government regulators, as the Company seeks to establish a new global standard for cannabis distribution practices. The technology integration and build-out is well underway, with management anticipating its use for customers in the recently announced agreements to export cannabis products internationally to South Africa and Australia (see press releases dated July 26th and July 29th, respectively).
Flora will use TruTrace’s blockchain-based SaaS software to track inventory and product quality testing, including molecular tagging through Applied DNA’s CertainT platform to track the cannabis flower and derivatives originating from its Cosechemos cultivation and extraction facility. The implementation of these technologies will ensure the products exported out of Colombia and delivered to global customers are derived directly from Flora’s operations, substantially reducing any concerns over counterfeit or illicit market products. Flora anticipates using this technology will further differentiate its low-cost, organically produced cannabis flower and derivatives from competitors as they can rest assured regarding the immutable journey these products traversed.
"In today’s globalized market, supply chain provenance is becoming an increasingly important component for every major international CPG company. This is particularly true for the cannabis industry, where concerns over the sale and distribution of products from the illicit market persist for businesses," commented Jason Warnock, Flora Growth’s Chief Revenue Officer. "Flora anticipates that the added assurance, efficiency, and transparency brought by these technologies will optimize our value proposition to customers, differentiate us from peers, and increase our sales opportunities."
"Agriculture is one of the oldest industries known to man, yet the technology necessary to support the cannabis industry continues to lag behind many others. This solution will empower Flora and its trading partners with tools needed to report and rapidly search through records in real-time," said Robert Galarza, CEO of TruTrace. "Today’s cannabis industry is desperately seeking legitimacy as it gains global acceptance, moving from the underworld of the illicit drug trade into a transparent and highly regulated emerging industry. The immutable power of big data is the key to that trust, and we applaud Flora Growth for launching this cutting-edge initiative to lead the charge in setting a new global standard for cannabis distribution."
"We are pleased for the opportunity to empower Flora’s global supply chain strategy with our CertainT platform," stated Dr. James Hayward, President and CEO of Applied DNA. "Through our integration with TruTrace, we are injecting an unprecedented level of transparency, traceability, and trust into cannabis supply chains reflective of Flora’s commitment to its global customer base."
About TruTrace & Applied DNA Technologies
TruTrace’s blockchain-based SaaS software is designed to guarantee product quality and strain genetic authenticity throughout global supply chains. Protecting consumers and brands from contaminants and counterfeiting is a key benefit of the platform under development. Shoppers Drug Mart, Canada’s largest retail pharmacy chain, currently uses the TruTrace platform as its underpinning technology infrastructure for traceability and accountability associated with its medical cannabis program.
Applied DNA’s CertainT® platform provides the physical tagging of cannabis products using a unique molecular tag to represent the brand and product. That tag is then tested at key nodes within a domestic or international supply chain. All authentication and chain-of-custody data is captured in the CertainT portal and integrated into the TruTrace platform. The molecular tag can be applied to cannabis products such as plants, oils, lotions, tablets, edibles, and their packaging to serve as an immutable indicator of authenticity, origin, and provenance.
Warrant Exercise Update
Flora Growth is also pleased to announce it has now received over US$10 M in cash receipts for warrant exercises. This represents a major milestone for the Company, with over half of all warrants from the Regulation A+ offering now in process of being exercised.
About TruTrace Technologies Inc.
TruTrace Technologies is the developer of fully-integrated software, secured on a blockchain infrastructure, that gives clients’ the ability to store, manage, share and immediately access quality assurance and testing details, COAs, as well as motion and movement intelligence on inventory. The platform was specifically designed to power the traceability of testing standards within the legal cannabis, nutraceutical, food and pharmaceutical space with a focus on the authentication of source materials or ingredients used in formulation. For more information, please visit www.trutrace.co.
About Applied DNA Sciences Inc.
Applied DNA is a provider of molecular technologies that enable supply chain security, anti-counterfeiting and anti-theft technology, product genotyping, and pre-clinical nucleic acid-based therapeutic drug candidates. Visit adnas.com for more information.
About Flora Growth Corp.
Flora is a cannabis company that leverages natural, cost-effective cultivation practices to supply cannabis derivatives to its diverse business divisions of cosmetics, hemp textiles, and food and beverage. As the operator of one of the largest outdoor cultivation facilities, Flora strives to market a higher-quality premium product at below market prices. By prioritizing natural ingredients and value-chain sustainability across its portfolio, Flora creates premium products that help consumers restore and thrive. Visit www.floragrowth.ca or follow @floragrowthcorp on social for more information.
Cautionary Statement Concerning Forward-Looking Statements
This document contains forward-looking statements. In addition, from time to time, we or our representatives may make forward-looking statements orally or in writing. We base these forward-looking statements on our expectations and projections about future events, which we derive from the information currently available to us. Such forward-looking statements relate to future events or our future performance, including: Flora’s supply chain strategy; the size of markets for cannabis and cannabis products; our financial performance and projections; our growth in revenue and earnings; and our business prospects and opportunities. You can identify forward-looking statements by those that are not historical in nature, particularly those that use terminology such as "may," "should," "expects," "anticipates," "contemplates," "estimates," "believes," "plans," "projected," "predicts," "potential," or "hopes" or the negative of these or similar terms. In evaluating these forward-looking statements, you should consider various factors, including: our ability to change the direction of the Company; our ability to keep pace with new technology and changing market needs; and the competitive environment of our business. These and other factors may cause our actual results to differ materially from any forward-looking statement. Forward-looking statements are only predictions. The forward-looking events discussed in this document and other statements made from time to time by us or our representatives may not occur, and actual events and results may differ materially and are subject to risks, uncertainties and assumptions about us. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of uncertainties and assumptions, or the forward-looking events discussed in this document and other statements made from time to time by us or our representatives not occurring, except as may be required by applicable law.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210908005687/en/
Contacts
Investor Relations Contact:
Evan Veryard
evan.veryard@floragrowth.ca
Public Relations Contact:
Cassandra Dowell
+1 (858) 264-6600
flora@cmwmedia.com
TTTSF Also nice to see Shoppers Drug Mart alliance confirmed.
From the Press Release:
"TruTrace’s blockchain-based SaaS software is designed to guarantee product quality and strain genetic authenticity throughout global supply chains. Protecting consumers and brands from contaminants and counterfeiting is a key benefit of the platform under development. Shoppers Drug Mart, Canada’s largest retail pharmacy chain, currently uses the TruTrace platform as its underpinning technology infrastructure for traceability and accountability associated with its medical cannabis program."
Two senior FDA officials stepping down.
https://endpts.com/breaking-in-a-major-blow-to-vaccine-efforts-senior-fda-leaders-stepping-down-report/
You were right about CLVR warrants being cheap, eom7. Warrant volume finally kicked up last few days.
And this is how it starts. You called it!
https://www.local10.com/news/florida/2021/08/12/desantis-sets-plan-for-regeneron-and-monoclonal-antibodies-to-fight-covid-19/
Definitely made the "Hm, gonna check that out" bucket.
Yup, SQ reversed minutes after open. Just enough time to grab and already flip some calls.
CLWRW, eom7? Can't find ticker.
Love Clever Leaves (CLVR) as a longer term pot play. Columbian President chose their grow site to announce Decree allowing export of flower last week. Check out their Twitter.
https://twitter.com/clever_leaves?ref_src=twsrc%5Egoogle%7Ctwcamp%5Eserp%7Ctwgr%5Eauthor
Nice Motley Fool mention today:
https://www.fool.com/investing/2021/07/28/3-growth-stocks-to-globalize-your-portfolio/
TLRY's results were a pleasant surprise. Lots of profitable reports should follow from the rest of the sector.
CLVR Clever Leaves to Take Advantage of the Approval to Export Medical Cannabis Flower from Colombia
July 23 2021 - 05:46PM
GlobeNewswire Inc.
Clever Leaves Holdings Inc. (Nasdaq: CLVR) (“Clever Leaves” or the “Company”), a multinational operator and licensed producer of pharmaceutical-grade cannabinoids, hosted Colombian President Duque at its cultivation facility in Colombia for the signing of a new decree that allows Colombian licensed cannabis companies such as Clever Leaves to participate in the commercial production and export of medical cannabis flower. With flower representing an estimated 50% of the global medical cannabis markets, this decree doubles the total addressable market for Colombian cannabis producers.
Clever Leaves is well-positioned to take advantage of this opportunity to export dried cannabis flower, leveraging its 1.8 million sq. ft. CUMCS GACP certified cultivation facility, its EUGMP Part II certification covering the production of dry flower, and its 30-plus cannabinoid genetics registered in the country. Colombia’s environmental conditions, coupled with Clever Leaves’ experience in sustainable cannabis growing, will allow the company to bring to market unique products with pharmaceutical quality. Colombian flower complements Clever Leaves’ already strong Portuguese flower production, allowing the company to present a comprehensive portfolio, covering different strains and growing conditions, that will suit ever-evolving patient needs.
Having shipped cannabis products to over 15 countries in five continents, Clever Leaves has a strong network of partners globally, who will benefit from its broader flower offering. Clever Leaves will leverage its position as a trusted B2B partner to develop and produce high quality and innovative products for medical cannabis patients around the world.
This change in regulation, allowing for the export of dried flower, will catalyze the continued development of the Colombian medical cannabis industry by eliminating the restriction that blocked access to 50% of the global medical cannabis market. In addition, the decree includes features that will help Clever Leaves to drive additional growth, including streamlined processes in quota management systems, which enable efficiencies and improve Clever Leaves’ ability to serve clients faster. The bill also includes access to medical cannabis for patients in Colombia.
During the visit to Clever Leaves’ facilities, President Duque, who was accompanied by several of his ministers, regional and local authorities, highlighted the expected impact of this to the country: “This new decree represents an important milestone for Colombia, enabling us to compete in international markets. Furthermore, the decree raises the standards of our products and adds significant value, particularly in the medicinal sector. Clever Leaves has served as a benchmark for the Colombian cannabis industry, generating 17 employments per hectare at its cultivation facility. I encourage our government representatives across various entities to unite and further support the development of the industry.”
Kyle Detwiler, CEO at Clever Leaves said: “The change in policy by the Colombian government could double our addressable market from Colombia, a region where Clever Leaves has made a substantial capacity investment but where we have been limited in only selling processed or extracted products up to this point in time. Nevertheless, since 2016, we have been building the capabilities required to produce a pharmaceutical-grade product.
“This regulatory evolution will enable us to better serve our customers around the world by capitalizing on Latin America’s only EU GMP certified cannabis operation, which, much to many peoples’ surprise, already includes EU GMP certified dry flower production. In hopeful anticipation of this moment, our team has spent the past several years developing commercial relationships, market insights and supply partnerships globally, and this catalyst will hopefully unlock significant potential of our gradually expanding customer base. Through our Portuguese dry flower production facility, we have learned and successfully navigated the different challenges facing a flower operation, including quality requirements, GACP and EU GMP certifications, sterility protocols, import/export logistics of psychoactive product, and cannabinoid potency requirements, many of which are different from that of processed or extracted products. We hope these lessons and relationships allow Clever Leaves to capitalize on Colombia’s new cannabis regulations.”
___________________________________
1 Market size estimates calculated from data reported in:
Grandview Industry Analysis, Legal Marijuana Market Size, Share & Trends Analysis Report By Marijuana Type (Medical, Adult Use), By Product Type (Flower, Oil), By Medical Application (Chronic Pain, Mental Disorders), And Segment Forecasts, 2021 – 2028. May 2021
BDS Analytics, Arcview Market Research, The State of Legal Cannabis Markets, 7th Edition, 2020 Update.
About Clever Leaves Holdings Inc.
Clever Leaves is a multinational cannabis company with an emphasis on ecologically sustainable, large-scale cultivation and pharmaceutical-grade processing as the cornerstones of its global cannabis business. With operations and investments in the United States, Canada, Colombia, Germany and Portugal, Clever Leaves has created an effective distribution network and global footprint, with a foundation built upon capital efficiency and rapid growth. Clever Leaves aims to be one of the industry’s leading global cannabis companies recognized for its principles, people, and performance while fostering a healthier global community. Clever Leaves has received multiple international certifications that have enabled it to increase its export and sales capacity from its Colombian operations, including European Union Good Manufacturing Practices (EU GMP) Certification, a Good Manufacturing Practices (GMP) Certification by Colombia National Food and Drug Surveillance Institute - Invima, and Good Agricultural and Collecting Practices (GACP) Certification. Clever Leaves was granted a license in Portugal from Infarmed – the Portuguese health authority – which allows Clever Leaves to cultivate, import and export dry flower for medicinal and research purposes. In addition, the Portuguese operation was granted certification of compliance with GACP and IMC-GAP.
For more information, please visit https://cleverleaves.com/en/home/ and follow us on LinkedIn.
Clever Leaves Investor Inquiries:
Cody Slach and Jackie Keshner
Gateway Investor Relations
+1-949-574-3860
CLVR@gatewayir.com
Clever Leaves Press Contacts:
McKenna Miller
KCSA Strategic Communications
+1-347-487-6197
mmiller@kcsa.com
Diana Sigüenza
Strategic Communications Director
+57-310-236-8830
diana.siguenza@cleverleaves.com
Clever Leaves Commercial Inquiries:
Andrew Miller
Vice President Sales - EMEA, North America, and Asia-Pacific
+1-416-817-1336
andrew.miller@cleverleaves.com
Citigroup Inc. Acquires New Holdings in Clever Leaves Holdings Inc. (NASDAQ:CLVR)
Posted by Logan Wallace on Jul 23rd, 2021
Clever Leaves logoCitigroup Inc. acquired a new stake in Clever Leaves Holdings Inc. (NASDAQ:CLVR) during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor acquired 11,948 shares of the company’s stock, valued at approximately $123,000.
Other hedge funds and other institutional investors have also modified their holdings of the company. UBS Group AG acquired a new stake in Clever Leaves in the 1st quarter valued at about $43,000. Wells Fargo & Company MN acquired a new stake in Clever Leaves in the 4th quarter valued at about $50,000. Vontobel Holding Ltd. acquired a new stake in Clever Leaves in the 4th quarter valued at about $142,000. Symons Capital Management Inc. purchased a new position in Clever Leaves in the 1st quarter valued at about $184,000. Finally, JPMorgan Chase & Co. purchased a new position in Clever Leaves in the 1st quarter valued at about $216,000. 19.53% of the stock is currently owned by hedge funds and other institutional investors.
Get Clever Leaves alerts:
NASDAQ:CLVR opened at $9.07 on Friday. The company has a debt-to-equity ratio of 0.42, a quick ratio of 2.44 and a current ratio of 2.82. The company has a 50-day moving average price of $10.04. Clever Leaves Holdings Inc. has a 12-month low of $7.95 and a 12-month high of $19.46.
Clever Leaves (NASDAQ:CLVR) last released its earnings results on Monday, May 17th. The company reported ($0.36) earnings per share (EPS) for the quarter. The business had revenue of $3.48 million for the quarter.
Clever Leaves Profile
Clever Leaves Holdings Inc cultivates, extracts, manufactures, and commercializes pharmaceutical-grade cannabinoid products in Colombia, Portugal, Germany, the United States, and Canada. The company operates through two segments, Cannabinoid and Non-Cannabinoid. It also engages in the formulating, manufacturing, marketing, distributing, and selling of homeopathic and other natural remedies, wellness products, detoxification products, nutraceuticals, and nutritional and dietary supplements for mass retailers, specialty and health retailers, and distributors.
Read More: Diversification Important in Investing
Want to see what other hedge funds are holding CLVR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Clever Leaves Holdings Inc.
So, the NRXP halt at 3:47 was just a volatility halt. Interesting.
NRXP halted on approval?
Did this HGEN mention contribute to middle of the night pop?
Vaccine business helps Lonza lifts 2021 sales outlook
3:18 AM ET 7/23/21 | Reuters
UPDATE 2-Vaccine business helps Lonza lifts 2021 sales outlook
* Sales and earnings beat forecasts during H1
* Company raises sales guidance for full year
* Plans to increase capex during H2 to raise production (Adds details, analyst comment, share price)
By John Revill
ZURICH, July 23 (Reuters) - Swiss contract drugmaker Lonza lifted its 2021 outlook on Friday after sales for the first half of the year beat analyst expectations as it benefits from a booming business making ingredients for COVID-19 vaccines.
The company, which has intensified agreements with vaccine producer Moderna, posted a 13.3% jump in sales to 2.54 billion Swiss francs ($2.76 billion), beating analyst forecasts for 2.47 billion francs.
Lonza now expects sales to increase in constant exchange rates towards the mid-teens percentage level for 2021, up from its previous forecast for sales growth in the low double-digit range.
Core earnings before interest, tax, depreciation and amortisation (EBITDA) rose 13% to 847 million francs, beating the 787 million francs forecast in a company-gathered poll of analysts.
The margin dipped to 33.3% from 33.4% a year earlier, but Lonza said it still expected to improve it this year.
Lonza shares, which have outpaced the blue-chip Swiss Market Index by rising 19.4% in 2021, were 2.1% higher in early trading.
Customer demand for COVID-related projects had continued during the first half, the company said, including for the drug substance production of Moderna's COVID-19 vaccine at Lonza's sites at Visp in Switzerland and Geleen in the Netherlands.
The company had responded by spending 474 million francs on capex, with the vast majority going towards increasing production levels. Total spending on its factories is expected to increase in the second half of the year, Lonza said.
"Our COVID-related collaboration with Moderna on the mRNA platform has undergone a series of expansions over the course of H1," said Chief Executive Pierre-Alain Ruffieux
"In April 2021, we expanded our collaboration to establish three further production lines in Visp. We have already started work on the installation, and we currently expect to commence ramp-up in early 2022."
Following a further expansion in the Moderna agreement in June, a further production line will be added at Geleen, which will start ramping up production of drug ingredients at the end of this year, he added.
As well as Moderna, Lonza has won COVID-19 contracts with AstraZeneca, Capriocor Therapeutics and Humanigen
"As we look more widely at our contribution through the pandemic, we have achieved our commitment to deliver for customers throughout this challenging period by expanding production and increasing headcount," the CEO said. ($1 = 0.9200 Swiss francs) (Reporting by John Revill; Editing by Shailesh Kuber and Keith Weir)
Guess I don't even have to ask about underwear, right?
Is this an accurate story?
https://tokenist.com/new-nscc-rule-change-poised-to-end-the-short-squeeze-saga/
Need "Likes" button on IHUB. You Fun Boys would be racking them up.
Can you get me a deal on the truck?
Add this to TSLA's woes...
https://www.greencarreports.com/news/1132453_tesla-model-3-and-model-y-recalled-for-potential-brake-issue
Did you and EdF watch this together?
I know it's close to both of your hearts.
https://www.cnbc.com/etf-edge/
With GME, I didn't have your level of certainty and bailed out close to the beginning when it stalled at $20. Never got back in. HGEN, on the other hand, checks all my boxes and I share your enthusiasm and conviction that this is one well worth the wait and the commitment to keep adding on each opportunity.
Not being one to turn down gifts, I keep adding.
Waiting for the day he has to acknowledge the "guy from Kentucky" and his Twitter stock HGEN was right.
See this last night? Hysterical.
Worth the time to watch his video.
https://www.cnbc.com/2021/05/26/jim-cramer-investors-who-are-short-gamestop-amc-are-out-of-their-mind.html
Caught .45 GLDFF (pot stock) this morning off 1 for 23 R/S today. $1.08 is the converted price.
MORE Act up for vote this week, I think. Most pot stocks having great day.
Love NVDA, but looks ripe for fin Puts.
MWM, thanks for BYND. Love the quick winners.
Did I just see what I thought I saw in the last hour of HGEN trading??? How many shares is that costing NOMIS?
Low energy use, but noxious gas would be overwhelming. However, there's another upside to producing the coins, but you've probably already factored it in.
One rumor is Rivian going to PSTH or IPOF.